Type 2 Diabetes Mellitus
Conditions
Interventions
No therapeutic interventions. Patients are asked to complete PROs at three different time points (baseline, Month 3, Month 6).
Sponsors
Sanofi
Eligibility
Inclusion criteria
Inclusion criteria: * T2DM patients on basal insulin for at least 3 months + metformin ± sulfonylureas; * For which the Investigator has decided to prescribe IGlarLixi independently from entry in the study (within 1 week of study entry); * BMI = 30 kg/m2 * = 18 years of age
Exclusion criteria
Exclusion criteria: * Diagnosis for T1DM; * Use of mealtime insulin or premix insulin within 6 months before switching to IGlarlixi; * Current use of GLP-1 RA; * Hypersensitivity to IGlarLixi or any of its components; * Pregnant (or intention to become pregnant during the course of the registry) or breast-feeding woman; * Incapability to fill in PRO questionnaires (at the discretion of the investigator)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Mean change in HbA1c between baseline to study end (week 24) | — |
Secondary
| Measure | Time frame |
|---|---|
| * Mean change in PRO score from baseline to week 12 and from baseline to study end (week 24); ? WHO-5 - emotional well-being (5 items) ? IWQOL-LITE – Impact of weight on quality of life (5 domains, 31 items) ? SDSCA – 1 item medication-adherence ? DMSRQ – treatment satisfaction/convenience * Mean change in HbA1c between baseline and week 12; * The percentage of patients reaching HbA1c <7% after 24 weeks; * Mean change in body weight and BMI between baseline and week 12 and week 24; | — |
Contacts
Public ContactThera Max- Mos
Sanofi
Outcome results
None listed